# A Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Gaucher Disease

> **NCT00430625** · PHASE3 · COMPLETED · sponsor: **Shire** · enrollment: 25 (actual)

## Conditions studied

- Gaucher Disease, Type 1

## Interventions

- **BIOLOGICAL:** VPRIV ®,

## Key facts

- **NCT ID:** NCT00430625
- **Lead sponsor:** Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02-15
- **Primary completion:** 2009-04-01
- **Final completion:** 2009-04-01
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2021-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00430625

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00430625, "A Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Gaucher Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00430625. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*